Blinatumomab is standard of care for children with relapsed acute lymphoblastic leukemia (ALL) and in de novo pediatric ALL for those who cannot tolerate or are resistant to conventional chemotherapy.
Advanced centres are able to provide blinatumomab as of fall 2024.
Desiree Naylor, Community Services Lead and Pediatric Portfolio Lead at the LLSC, hosted an educational session on blood cancer resources for patients, caregivers and HCPs on May 22, 2024.